15 results about "Blood coagulation time" patented technology

The invention relates to a method for determining a fibrinogen concentration in a blood sample, comprising whole blood, the sample having been mixed with a reagent configured to cause fibrin formation, the method comprising: - a) forming images (I(t)) of the sample at various times (t); - b) establishing a correlation indicator (C(t)) between images acquired at various respective times (I(t), (I(t + dt))); - c) determining a variation as a function of time in the correlation indicator; - d) detecting a coagulation time (tcoag) on the basis of the variation as a function of time; - e) depending on the coagulation time, determining the fibrinogen concentration in the blood; the method being characterised in that: the reagent comprises batroxobin, the batroxobin concentration, after mixing, being between 25 and 1000 enzyme units per mL.

A blood coagulation time shortening agent for a blood specimen deficient in coagulation factor XII, in activated partial thromboplastin time measurement includes, as an active ingredient, a polymer having 2-methacryloyloxyethyl phosphorylcholine as a constitutional unit.

The invention relates to the technical field of biomass resource utilization and medical biological materials, in particular to a method for preparing a hemostatic sponge based on sunflower stem pith and application of the hemostatic sponge. The hemostatic sponge is prepared from sunflower stem pith fragments and an adhesive through a deconstruction-recombination technology and meets the requirements of isotropic liquid absorption, non-isotropic liquid absorption and non-isotropic liquid absorption; the difference between the axial blood suction rate and the radial blood suction rate is smaller than or equal to 10%, the shape memory recovery rate within 30 seconds after blood suction is larger than or equal to 85%, and the blood coagulation time is 60-100 seconds. According to the sunflower stem pith-based hemostatic sponge, sunflower byproducts serve as raw materials, the water absorption capacity and the hemostatic efficiency of the sponge are improved by means of the hydrophilicity and the procoagulant characteristic of the sunflower byproducts, and the raw material cost is reduced by 90% or above compared with that of existing synthetic sponge; the sunflower stem pith-based hemostatic sponge is constructed based on deconstruction and structural recombination, the limitation of a natural sunflower stem pith anisotropic microstructure is improved, the sponge has isotropic liquid absorption, the difference between axial and radial blood absorption rates is smaller than or equal to 10%, the sponge has shape memory ability, the sponge is compressed to 50% of the original volume after blood absorption, and the recovery rate is larger than or equal to 85% within 30 s.

A method for determining the concentration of fibrinogen in a blood sample, comprising whole blood, the sample having been mixed with a reagent configured to induce fibrin formation, the method comprising: a) forming images of the sample at different times; b) establishing a correlation indicator between images respectively acquired at different times; c) determining a time evolution of the correlation indicator; d) detecting a coagulation time from the time evolution; e) as a function of the coagulation time, determining the concentration of fibrinogen in the blood; the method being characterized in that: the reagent comprises batroxobin, the concentration of batroxobin, after mixing, being between 25 and 1000 enzyme units per mL.

A blood collection tube (1) into which a blood sample has been placed is irradiated with near-infrared light having a specific wavelength of 1050-1350 nm by means of a near-infrared light source (4), and the process of a blood coagulation reaction can be observed by measuring the temporal change in light intensity passing through the inside of the blood sample detected by an infrared camera (6). Thus, in addition to measuring the blood coagulation time, it is possible to determine the completion or non-completion of the blood coagulation reaction on the basis of the tendency to increase or decrease the light intensity, and it is possible to automate the pre-treatment step of the centrifugal separation treatment.

The invention belongs to the technical field of application of traditional Chinese medicines, and particularly relates to application of a Dan'e Fukang preparation in preparation of a medicine for treating dysfunctional uterine bleeding. Pharmacological experiments prove that Dan'e'fukang can shorten the blood coagulation time and bleeding time of mice, and increase the uterine coefficient, estradiol level and progesterone level of rats without ovulation type dysfunctional uterine bleeding and the VEGF protein expression quantity of endometrial tissues of the rats. The Dan'e Fukang provides more medication choices for clinical treatment of dysfunctional uterine bleeding diseases, and has the advantages of good effect, many years of clinical use experience and high safety.

The invention relates to the technical field of heparin and protamine analysis, in particular to a method for determining the dosage of heparin and protamine. The method comprises the steps that a first sample set A is obtained, Ai is the ith first sample, and Ai is obtained by adding different doses of preset chemical substances into a blood sample of a target individual; acquiring a whole blood activation blood coagulation time detection result set B; obtaining a target model according to the whole blood activation coagulation time detection result in the step B, the dosage of the corresponding added preset chemical substance and the preset model; and according to the target whole blood activated coagulation time and the target model, obtaining the dosage of a preset chemical substance corresponding to the target whole blood activated coagulation time of the target individual. According to the method, the heparin dosage and the protamine dosage which are suitable for the target individual and correspond to the target whole blood activation coagulation time can be determined, and reference is provided for the heparin dosage and the protamine dosage in an actual application scene.

A method for controlling MNPT is required.Coexistence of a specific metal ion with tissue thromboplastin enables MNPT to be controlled / adjusted to a desired time. Coexistence of the specific metal ion with tissue thromboplastin also enables improvement of stability when a thromboplastin reagent is stored in a solution form.

The application discloses a blood coagulation detector, which comprises a driving motor, a blood coagulation cylinder, a connecting rod, a sealing cover, a magnet, a base plate, a pressing plate, a polymer film, an elastic metal plate, an electrode, a working plane and an electrometer, wherein the driving motor is fixedly installed on the working plane, the rotating shaft of the driving motor is provided with the blood coagulation cylinder, the blood coagulation cylinder is provided with the magnet, the working plane is further provided with the base plate and the pressing plate which are fixedly bonded at an included angle, the included angle between the base plate and the pressing plate is an acute angle, the base plate is pasted with the polymer film, the pressing plate is inserted with the elastic metal plate, the elastic metal plate has elasticity, the front end of the elastic metal plate extends towards the polymer film, the front end of the elastic metal plate is fixedly provided with the electrode, the electrode is in contact with the polymer film, and the electrode is connected with the electrometer through the wire. The electrode and the polymer film are periodically contacted and separated to generate an electric signal, and the electric signal is read through the electrometer, so that the blood coagulation time and other parameters can be detected, and the sensitivity is high.

Provided is a method for accurately measuring coagulation time of blood samples showing various coagulation reactions. The method for measuring blood coagulation time includes measuring coagulation reaction of a sample prepared by mixing a subject specimen and a coagulation time measurement reagent; calculating weighted average time of a calculation target area of a waveform related to coagulation velocity from the resulting measurement data; and determining the weighted average time as blood coagulation time.

An activated partial thromboplastin time measurement reagent contains a polymer having 2-methacryloyloxyethyl phosphorylcholine as a constitutional unit. A blood coagulation time regulator for a lupus anticoagulant-positive blood specimen or a heparin-containing blood specimen in activated partial thromboplastin time measurement includes, as an active ingredient, a polymer having 2-methacryloyloxyethyl phosphorylcholine as a constitutional unit.

The invention provides novel multi-layer composite hemostatic gauze based on modified zeolite and a preparation method thereof. The gauze comprises a modified zeolite core layer from inside to outside, the content of Ca < 2 + > is increased to 6-13 wt% through ion exchange, 0.4-1.2 wt% of prothrombin activator is loaded, platelet activation is promoted through high-calcium zeolite, and the blood coagulation time is shortened to 46.7% of that of a conventional product. A temperature control buffer layer, a calcium alginate / polyethylene glycol hydrogel layer with the thickness of 5-10 [mu] m and a phase change material (octadecane microcapsule) containing 3-5 wt%, the phase change material generates phase change heat absorption at 42 DEG C, and the heat release peak value of zeolite is controlled to be 42 DEG C or below. The outer carrier is viscose fiber / silk blended gauze subjected to plasma treatment. The multi-layer composite zeolite hemostatic gauze can be applied to medical instruments for emergency treatment of war wounds, hemostasis in surgical operations and bleeding control of patients in anticoagulation treatment.

The invention relates to application of a cytoskeleton regulator in preparation of a blood coagulation promoting drug, and belongs to the technical field of biological medicines, and the blood coagulation promoting drug is a drug for treating or preventing hemorrhagic diseases related to low blood coagulation function. The hemorrhagic diseases comprise traumatic hemorrhage, surgical operation related hemorrhage, hepatopathy related hemorrhage, postpartum hemorrhage, hemophilia, hemorrhage caused by excessive anticoagulant drugs, thrombocytopenia or dysfunction related hemorrhage; the cytoskeleton regulator is one or more of a compound for inhibiting polymerization of actin microfilaments, a compound for inhibiting shrinkage of myosin and a ROCK kinase inhibitor; the cytoskeleton regulator can be used for preparing a procoagulant treatment drug, the effect is played by inducing endogenous cells of a body to release procoagulant particles, a brand new strategy is provided for a clinical hemostatic drug, and the cytoskeleton regulator can remarkably shorten the coagulation time of whole blood; the bleeding time can be remarkably shortened, the total blood loss amount is reduced, and the powerful in-vivo bleeding stopping effect is achieved.

To estimate a cause of extension of coagulation time of the blood of a specimen to be inspected.SOLUTION: A method for estimating a cause of extension of blood coagulation time includes: acquiring a coagulation waveform indicating a change with time of a light amount due to a coagulation reaction of reaction liquid obtained by mixing a specimen to be inspected and an agent (S301b); acquiring a first waveform through before-and-after difference processing on the coagulation waveform (S302b); acquiring first and second fitting waveforms through fitting processing on the coagulation waveform and the first waveform (S303b, S304b); acquiring a third waveform through the before-and-after difference processing on the second fitting waveform (S305b); acquiring first to third normalized waveforms by normalizing light amount axes and time axes of the first and second fitting waveforms and the third waveform (S306b); extracting a feature quantity from each of the first to third normalized waveforms (S307b); and estimating the cause of extension of the coagulation time of the blood of the specimen to be inspected on the basis of a known feature quantity and the extracted feature quantity.SELECTED DRAWING: Figure 3B

The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX / F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44 / B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.